A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Trial Profile

A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 03 Jan 2017 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.
    • 03 Jan 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
    • 03 Jan 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top